The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
February 29, 2016
View Complete Issue         Table of Contents 2019 
Olaparib (Lynparza) for Advanced Ovarian Cancer (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Olaparib (Lynparza) for Advanced Ovarian Cancer (online only)
February 29, 2016 (Issue: 1489)
The FDA has approved the oral poly (ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza – Astra-Zeneca) as monotherapy for treatment of women with advanced ovarian cancer who have BRCA1/2 germline mutations and have received at least 3...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Olaparib (Lynparza) for Advanced Ovarian Cancer (online only)
Article code: 1489e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.